Navigation Links
Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
Date:8/31/2009

MONT-SAINT-GUIBERT, Belgium, August 31 /PRNewswire/ --

- Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies

Cardio3 BioSciences, today provided an update and review of the clinical development of its unique C-Cure(R) therapy at the European Society of Cardiology Congress in Barcelona. A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure, one of the world's largest unmet medical needs.

The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.

The session was led by Prof. Stephanie Dimmeler (Institute for Cardiovascular Regeneration, Goethe University Frankfurt) and Prof. Michael Tendera (Head, Cardiology Division, Medical University of Silesia, Katowice, Poland) and included cardiology experts from leading European and U.S institutions: Dr Josef Bartunek (Cardiovascular Center Aalst, Belgium), Professors Dominique Charron (St Louis Hospital, Paris, France), Helmut Drexler (Hannover Medical school, Germany), Andre Terzic (Mayo Clinic, Rochester U.S.A) and Catherine Verfaillie (Leuven University, Belgium).

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "The potential of cell therapies for the treatment of heart failure has long been recognised but there have been considerable hurdles to overcome in delivering on the promise. Today's expert panel was able to provide a thorough review of the advancements in science that have brought about today's second generation cell therapies and to put our product, C-Cure, into context. We believe C-Cure has tremendous potential to realise the promise of regenerative therapies in heart failure and look forward to the results of our pivotal trial."

C-Cure draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient's own bone marrow cells and through a proprietary culturing technology, gives rise to 'cardiopoietic' cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

    For more information contact:
    Cardio3 BioSciences
    Mayra Beydoun, Brand & Communication Manager
    Tel : +32-10-39-41-00
    mbeydoun@c3bs.com
   http://www.c3bs.com

    Citigate Dewe Rogerson
    Chris Gardner/Nina Enegren
    Tel : +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk
    nina.enegren@citigatedr.co.uk


'/>"/>
SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... ... public interest organization focused on molecular nanotechnology, announced the winners for the 2015 ... pioneer physicist Richard Feynman, are given in two categories, one for experiment and ...
(Date:5/20/2016)... , ... May 20, 2016 , ... The leading Regenerative ... its most experienced veterinary clients have treated over 100 of their own patients with ... to provide the highest level of care for their patients. , The veterinarians ...
(Date:5/20/2016)... ... ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, in malignant ... Surviving Mesothelioma has just posted an article on the new study. Click here ... study on the fact the Manumycin A, a derivative of Streptomyces parvulus, is known ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located ... foot office building is complete. The new structure adds a third office building to ... Paar USA purchased 2.4 acres of land, along with office space adjacent to ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):